Table 1 Results of diagnostic tests in pediatric patients with proven or probable invasive mold disease of the central nervous system.

From: Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children

Pt #

Age/sex

Underl. diagnosis

Culture CNS

Micros. CNS

GM CNS

GM BAL

GM blood

PCR CNS

PCR BAL

PCR blood

Culture BAL

Pathol. BAL

Pathol. other sites

infection outside CNS

CNS infection

1

16.6 /m

ALL

negativea

hyphaea

n.d.

n.d.

7.5

A. fum.a

n.d.

n.d.

n.d.

n.d.

hyphaed

proven

proveng, h

2

17.1/f

AML (HSCT)

n.d.

hyphaea

n.d.

n.d.

0.5

A. fum.a

n.d.

n.d.

n.d.

n.d.

hyphaee

proven

proveng

3

15.2/f

AML (HSCT)

n.d.

n.d.

n.d.

n.d.

n.d.

Fusarium sppa

n.d.

Fusarium spp

n.d.

n.d.

n.d.

proven

probableg

4

17.9 /m

ALL

negativeb

n.d.

2.7b

3.0

2.0

n.d.

A. fum.

n.d.

negative

n.d.

n.d.

proven

probableg

5

3.8/f

ALL

n.d.

hyphaea

5.4b

n.d.

negative

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

probable

proveng, h

6

3.1 /m

SCI (HSCT)

n.d.

hyphaea

n.d.

n.d.

5.2

negativeb

n.d.

n.d.

n.d.

hyphae

n.d.

proven

provenh

7

17.7 /m

ALL (HSCT)

negativeb

hyphaea

n.d.

n.d.

negative

negativea

negative

n.d.

n.d.

hyphae

n.d.

proven

proveng

8

3.8/f

ALL

n.d.

hyphaea

negativeb

n.d.

0.8

A. fum.a

n.d.

n.d.

n.d.

n.d.

hyphaef

proven

proveng

9

16.3 /m

ALL

n.d.

n.d.

n.d.

1.2

negative

A. fum.b

n.d.

n.d.

A. fum.

n.d.

n.d.

proven

proveng, h

10

10.6 /m

ALL

negativeb

n.d.

4.5b

12.3

5.7

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

probable

probableg– i

11

17.5 /m

CML (HSCT)

negativeb

n.d.

negativeb

2.0

negative

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

probable

probableg

12

5.1/f

ALL

negativec

hyphaea

0.6b

n.d.

negative

A. fum.b

n.d.

n.d.

n.d.

n.d.

n.d.

possible

proveng, h

13

16.9 /m

ALL

negativeb

n.d.

negativeb

9.8

0.6

n.d.

n.d.

n.d.

negative

n.d.

n.d.

probable

probableg

14

5.7 /m

ALL

negativeb

n.d.

negativeb

7.3

negative

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

probable

probable h, i

15

18.0 /m

CGD (HSCT)

negativeb

n.d.

6.4b

n.d.

2.5

n.d.

n.d.

n.d.

n.d.

hyphae

n.d.

proven

probableg, h

  1. Pt patient; f female; m male; ALL acute lymphoblastic leukemia, AML acute myeloid leukemia; HSCT hematopoietic stem cell transplantation; SCI severe immunodeficiency; CML chronic myeloid leukemia; CGD chronic granulomatous disease; CNS central nervous system; micros microscopy; n.d. not done; CSF cerebrospinal fluid; GM galactomannan; BAL broncho-alveolar lavage; A. fum. Aspergillus fumigatus.
  2. Assay performed in abiopsy, bCSF, or cbiopsy and CSF
  3. Pathological sites outside the CNS were dgut, eeye, and fappendix
  4. Imaging findings were gfocal lesions, hhemorrhage/infarction, and imeningitis.